OBJECTIVE: To develop a prognostic model to predict disease outcomes in individual patients with Parkinson disease (PD) and perform an external validation study in an independent cohort. METHODS: Model development was done in the Comorbidity and Aging in Rehabilitation Patients: The Influence on Activities (CARPA) cohort (Netherlands). External validation was performed using the Cambridgeshire Parkinson's Incidence from GP to Neurologist (CamPaIGN) cohort (UK). Both are longitudinal incident cohort studies that prospectively followed up patients with PD from the time of diagnosis. A composite outcome measure was made in which patients were classified as having an unfavorable prognosis when they had postural instability or dementia at the 5-...
The presentation and progression of Parkinson’s disease (PD) are not uniform, but the presence of ra...
OBJECTIVES:To use a data-driven approach to determine the existence and natural history of subtypes ...
Parkinson's disease is the second most common neurological disease and affects about 1% of persons o...
Parkinson disease (PD) has a relatively long prodromal period that may permit early identification t...
Acknowledgments We would like to thank study participants, study personnel, and study funders. Fundi...
OBJECTIVE: In Parkinson disease (PD), the rate of clinical progression is highly variable. To date, ...
Objective: To determine progression and prognostic factors of progression rate of motor impairment, ...
There are few established predictors of the clinical course of PD. Prognostic markers would be usefu...
BACKGROUND: There is a great need for the development of personalized prediction models (PPMs) that ...
BACKGROUND: Clinical trials of disease-modifying therapies in PD require valid and responsive primar...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
BackgroundParkinson's disease (PD) is a chronic, disabling neurodegenerative disorder.ObjectiveTo pr...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
Objectives To use a data-driven approach to determine the existence and natural history of subtypes ...
The presentation and progression of Parkinson’s disease (PD) are not uniform, but the presence of ra...
OBJECTIVES:To use a data-driven approach to determine the existence and natural history of subtypes ...
Parkinson's disease is the second most common neurological disease and affects about 1% of persons o...
Parkinson disease (PD) has a relatively long prodromal period that may permit early identification t...
Acknowledgments We would like to thank study participants, study personnel, and study funders. Fundi...
OBJECTIVE: In Parkinson disease (PD), the rate of clinical progression is highly variable. To date, ...
Objective: To determine progression and prognostic factors of progression rate of motor impairment, ...
There are few established predictors of the clinical course of PD. Prognostic markers would be usefu...
BACKGROUND: There is a great need for the development of personalized prediction models (PPMs) that ...
BACKGROUND: Clinical trials of disease-modifying therapies in PD require valid and responsive primar...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
BackgroundParkinson's disease (PD) is a chronic, disabling neurodegenerative disorder.ObjectiveTo pr...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
Objectives To use a data-driven approach to determine the existence and natural history of subtypes ...
The presentation and progression of Parkinson’s disease (PD) are not uniform, but the presence of ra...
OBJECTIVES:To use a data-driven approach to determine the existence and natural history of subtypes ...
Parkinson's disease is the second most common neurological disease and affects about 1% of persons o...